Patents by Inventor Helen L. Gibson

Helen L. Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120142099
    Abstract: The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.
    Type: Application
    Filed: January 19, 2011
    Publication date: June 7, 2012
    Applicant: GENENTECH, INC.
    Inventors: Michael C. Kiefer, Paul A. Fitzpatrick, Helen L. Gibson, Philip J. Barr
  • Patent number: 7914771
    Abstract: The present invention encompasses methods and compositions for the treatment and prevention of chronic obstructive pulmonary disease (COPD) or emphysema, typically smoking-induced emphysema. More specifically, the present invention relates to the treatment and prevention of COPD or emphysema by inhalation of alpha one-antitrypsin (AAT).
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: March 29, 2011
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Philip A. Pemberton, Helen L. Gibson
  • Patent number: 7892825
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: February 22, 2011
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Patent number: 7888038
    Abstract: The present invention provide polynucleotide sequences encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provide recombinant host cells containing polynucleotides encoding BBP. The invention further provide antibodies that specifically bind to BBP. The invention further provide methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provide methods for detecting the presence of Bak polynucleotides and the encoding proteins in a biological sample, and further provide methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: February 15, 2011
    Assignee: Genetech, Inc.
    Inventors: Michael C. Kiefer, Paul A. Fitzpatrick, Helen L. Gibson, Philip J. Barr
  • Patent number: 7709446
    Abstract: Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: May 4, 2010
    Assignee: Arrive Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson, Philip A. Pemberton
  • Publication number: 20090042278
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Application
    Filed: July 7, 2008
    Publication date: February 12, 2009
    Applicant: ARRIVA PHARMACEUTICALS, INC.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Patent number: 7419801
    Abstract: Vectors, host cells, and methods are provided for the production of proteins in yeast. The vectors generally contain a selection gene, a yeast 2 micron sequence, and a polynucleotide encoding a polypeptide, where the polynucleotide is operably linked to promoter, and where the polynucleotide contains one or more yeast-preferred codons. Host cells are cultured under conditions where, after an initial batch phase, oxygen concentration is kept high and glucose feed is regulated so that the yeast cells stay in respiratory metabolism.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: September 2, 2008
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson
  • Patent number: 7316915
    Abstract: The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: January 8, 2008
    Assignee: Tanox, Inc.
    Inventors: Michael C. Kiefer, Paul A. Fitzpatrick, Helen L. Gibson, Philip J. Barr
  • Patent number: 7247704
    Abstract: Fusion proteins of protease inhibitors are provided, in particular fusion proteins of alpha 1-antitrypsin (AAT) and a second protease inhibitor, such as secretory leukocyte protease inhibitor (SLPI) or tissue inhibitor of metalloproteases (TIMP). Polynucleotides encoding the fusion proteins, vectors comprising such polynucleotides, and host cells containing such vectors are also provided. Methods of making the fusion proteins of the invention are also provide, as well as methods of using the fusion proteins, for example to inhibit protease activity in a biological sample or in the treatment of an individual suffering from, or at risk for, a disease or disorder involving unwanted protease activity.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: July 24, 2007
    Assignee: Arriva Pharmaceuticals, Inc.
    Inventors: Philip J. Barr, Helen L. Gibson, Philip A. Pemberton
  • Publication number: 20030060615
    Abstract: The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention further provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which are involved in the interaction between Bak and BBP.
    Type: Application
    Filed: July 1, 2002
    Publication date: March 27, 2003
    Applicant: Tanox, Inc.
    Inventors: Michael C. Kiefer, Paul A. Fitzpatrick, Helen L. Gibson, Philip J. Barr
  • Patent number: 6441135
    Abstract: The present invention provides polynucleotide sequences (bbp) encoding a Bak Binding Protein (BBP) and fragments thereof that bind to Bak. The invention also provides a BBP which binds to Bak. The invention also provides recombinant host cells containing polynucleotides encoding BBP. The invention further provides antibodies that specifically bind to BBP. The invention further provides methods for detecting agents such as drugs that alter the binding of a BBP with a Bak protein. The invention neither provides methods for detecting the presence of bbp or BBP in a biological sample, and further provides methods for modulating the levels of BBP in a cell. This invention additionally encompasses novel peptides, designated the “BBP Binding Domains” and the respective nucleotides, designated “bbpbd-1” and “bbpbd-2” which arc involved in the interaction between Bak and BBP.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: August 27, 2002
    Assignee: Tanox, Inc.
    Inventors: Michael C. Kiefer, Paul A. Fitzpatrick, Helen L. Gibson, Philip J. Barr